Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-694

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

This text describes a visual aid, Figure 1, which shows the probability of achieving systolic blood pressure under 140 mmHg after 8 weeks of treatment with Valsartan and Hydrochlorothiazide, compared to placebo. The doses of the active ingredients are presented (320 mg and 25 mg respectively), as well as a baseline measurement of blood pressure. The number "2883223288" appears unrelated to the topic.*

FDA Label Image

63187-694-90 (Valhyctz Fig12)

This is a medication called Valsartan HCTZ 320mg / 25mg with product ID RV069490, manufactured by Aurobindo Pharma Limited in India. It contains 90 yellow, oval-shaped, film-coated tablets with 'I' on one side and '65' on the other side, and is stored at 20°-25°C (68°-77°F). It has a Master SN# and a lot number of 00000 with an expiration date of 00/00/00. It is RX only and should be kept out of reach of children. It has been relabeled by Proficient Rx LP in Thousand Oaks, CA 91320.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

This is a graph showing the probability of achieving diastolic blood pressure below 90 mmHg at week 8, based on different baseline DBP levels. The graph shows three different data points at 95, 100, and 105 for baseline DBP.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

The graph displays the probability of achieving a systolic blood pressure below 130 mmHg at week 8. The study involved the use of Valsartan and Hydrochlorothiazide at doses of 320mg/25mg and 284mg, respectively, compared to a placebo. The baseline systolic blood pressure ranged from 140-180 mmHg.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

This text describes a clinical trial evaluating the effectiveness of Valsartan and Hydrochlorothiazide in reducing diastolic blood pressure (DBP) below 80 mmHg. The trial tested a combination of Valsartan 320 mg and Hydrochlorothiazide 25 mg against a placebo, and the results are presented graphically in Figure 4, showing the probability of achieving the target DBP at Week 8.*

FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.